FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
7/28/2017
0:00
NaN:NaN:NaN
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017
More episodes from "FDA Drug Information Updates"
Don't miss an episode of “FDA Drug Information Updates” and subscribe to it in the GetPodcast app.